Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2019 Mar 1;17(13):2687–2695.e11. doi: 10.1016/j.cgh.2019.02.039

Figure 2:

Figure 2:

Sensitivity analysis identifying the optimal level of payer coverage for rifaximin (displayed by color at the corresponding point estimate) based on drug cost (y-axis) and assumed necessary interval of retreatment with rifaximin (x-axis).